AbbVie buys Pharmacyclics in a deal for 21 billion USD

Noam Stiekema

AbbVie buys Pharmacyclics in a deal for 21 billion USD. The company surpassed the offer of rival Johnson & Johnson to control revolutionary therapy of cancer of the blood that will enable it to develop in the field of oncology. Under the deal, the American producer of rare medicines AbbVie will pay 261.25 USD per […]

AbbVie

AbbVieAbbVie buys Pharmacyclics in a deal for 21 billion USD. The company surpassed the offer of rival Johnson & Johnson to control revolutionary therapy of cancer of the blood that will enable it to develop in the field of oncology. Under the deal, the American producer of rare medicines AbbVie will pay 261.25 USD per share in cash and new shares of AbbVie, announced in a statement the two companies on Thursday. The price was 39% above the closing price of the shares of Pharmacyclics Inc from 24th February 2015, the day before announcing the possibility of the deal.

Acquisitions will help AbbVie to reduce its dependence on Humira, best-selling product is the company’s treatment of arthritis. Now it will be able to expand in the field of cancer therapy, one of the most promising areas of development of pharmaceuticals. AbbVie will gain control over Imbruvica, easy to use pill that costs about 100 thousand dollars a year and helps to avoid some serious side effects of chemotherapy. It has already been approved for the four different types of leukemia.

Pharmacyclics led negotiations and almost had agreed to be acquired by Johnson & Johnson. The discussed price was 250 USD per share, but AbbVie made better offer at the last minute, said a source familiar with the situation. AbbVie expects about 58% of the transaction to be paid in cash and 42% – equity, and be completed by mid-year. Its shares rose 1.1 percent to 60.27 dollars a share in New York. Since separated from Abbott Laboratories in 2013, AbbVie had not been able to finish any of тхе мега-деалс that tempt most of the drug industry.

Read this next

Digital Assets

Zero Hash obtains AUSTRAC registration in Australia

Seed CX is expanding the reach of its crypto settlement solution, dubbed ‘Zero Hash,’ which has registered with the Australian Transaction Reports and Analysis Centre (AUSTRAC) as a digital currency exchange provider.

Digital Assets

UK advertising watchdog slams Arsenal over misleading crypto ads

The UK advertising watchdog has reprimanded Arsenal Football Club for promoting crypto assets without warning fans of the potential associated risks.

Retail FX

Swissquote profit slips as crypto revenue falls by two thirds

Swissquote Group, Switzerland’s provider of online trading services, reported that its H1 revenues dropped by nearly a quarter from a year ago as clients’ interest in crypto trading stagnated.

Digital Assets

Crypto.com granted approval to operate business in Cayman Islands

Crypto.com, one of the longest-established crypto platforms, has obtained a new registration in the Cayman Islands under the Virtual Asset Services Providers Act.

Executive Moves

United Fintech hires Mitch Vine and Danny Finnerty to expand US footprint

“United Fintech’s expansion in the US is pivotal to our mission of helping financial institutions digitize and gain access to best in class capital markets focused technology.”

Digital Assets

Ankr backed by Binance Labs after several initiatives in support of BNB Chain

Ankr has made a series of upgrades to the BNB Chain, including Erigon, the Archive Node, and the latest BNB Application Sidechain (BAS) scalability solution.

Retail FX

Financial Commission terminates membership of LordFX

The Financial Commission, an independent self-regulatory compliance specialist for the financial services industry, has expelled forex brokerage LordFX from its membership, according to a FinaCom statement.

Industry News

Match-Prime Liquidity sponsors Cypriot football club Omonoia FC

“We feel privileged to support Omonoia as it’s one of the largest teams in Cyprus, fandom size-wise, and we know it has a special connection with its supporters.”

Institutional FX

XTB’s X Open Hub adds 30 cryptos to white label offering for brokers

Its solutions include deep institutional liquidity on more than 5,000 global instruments, such as indices, shares, forex, cryptocurrencies, commodities, and ETFs, and a white label platform that can be fully customized and branded for each brokerage.

<